[go: up one dir, main page]

BR9712970A - Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica - Google Patents

Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica

Info

Publication number
BR9712970A
BR9712970A BR9712970-4A BR9712970A BR9712970A BR 9712970 A BR9712970 A BR 9712970A BR 9712970 A BR9712970 A BR 9712970A BR 9712970 A BR9712970 A BR 9712970A
Authority
BR
Brazil
Prior art keywords
respiratory syncytial
syncytial virus
protein
fusion protein
mixture
Prior art date
Application number
BR9712970-4A
Other languages
English (en)
Inventor
George A Cates
Sonia E Sanhueza
Raymond P Oomen
Michel H Klein
Original Assignee
Connaught Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24725423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9712970(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Connaught Lab filed Critical Connaught Lab
Publication of BR9712970A publication Critical patent/BR9712970A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18551—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)

Abstract

<B>PREPARAçãO DE VACINA DE VìRUS SINCICIAL RESPIRATóRIO DE SUBUNIDADE<D> Proteína de fusão (F), proteína acoplada (G) e a proteína matriz (M) de vírus sincitial respiratório (RSV) são isolados e purificados do vírus sincitial respiratório por extração com detergente brando das proteínas de vírus concentrados, carregados de proteína sobre um hidroxiapatide ou outro coluna matriz de troca iónica e extraindo a proteína utilizando um tratamento salino brando. As proteínas F, G, e M, formuladas como composições imunogênicas, são seguras, e altamente imunogênias, e protegem de forma relevante animais contra doenças causadas por infecção por vírus sincitial respiratório.
BR9712970-4A 1996-07-12 1997-07-11 Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica BR9712970A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/679,060 US6020182A (en) 1996-07-12 1996-07-12 Subunit respiratory syncytial virus vaccine preparation
PCT/CA1997/000497 WO1998002457A1 (en) 1996-07-12 1997-07-11 Subunit respiratory syncytial virus vaccine preparation

Publications (1)

Publication Number Publication Date
BR9712970A true BR9712970A (pt) 2001-08-28

Family

ID=24725423

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712970-4A BR9712970A (pt) 1996-07-12 1997-07-11 Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica

Country Status (14)

Country Link
US (2) US6020182A (pt)
EP (2) EP0942928B2 (pt)
JP (1) JP2000501418A (pt)
CN (1) CN1145639C (pt)
AT (1) ATE282633T1 (pt)
AU (1) AU716378B2 (pt)
BR (1) BR9712970A (pt)
CA (1) CA2259594C (pt)
DE (2) DE942928T1 (pt)
ES (1) ES2141065T5 (pt)
GR (1) GR990300042T1 (pt)
NZ (1) NZ334115A (pt)
RU (1) RU2243234C2 (pt)
WO (1) WO1998002457A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020136739A1 (en) * 1996-07-12 2002-09-26 Cates George A. Subunit respiratory syncytial virus preparation
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US6017694A (en) * 1997-12-19 2000-01-25 American Cyanamid Company Methods of screening for modulators of respiratory syncytial virus matrix protein interaction
NZ512980A (en) * 1998-12-17 2003-07-25 Aventis Pasteur Multivalent immunogenic composition containing RSV subunit composition and influenza virus preparation
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
WO2001006429A1 (en) * 1999-07-15 2001-01-25 Shea Robert S Method of sequencing chronic disease testing, reporting and evaluation
AU3480001A (en) * 2000-02-02 2001-08-14 Government of the United States as represented by the Secretary of the Department of Commerce, The CD40 ligand adjuvant for respiratory syncytial virus
FR2806912B1 (fr) * 2000-04-04 2004-07-23 Fond Mondiale Rech Et Preventi UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
WO2002009749A2 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Respiratory syncytial virus vaccine
AU2001281614A1 (en) * 2000-08-07 2002-02-18 Aventis Pasteur Limited Stabilization of immunogens derived from paramyxoviruses
DE60136381D1 (de) * 2000-10-18 2008-12-11 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
EP1441762A1 (en) * 2001-09-28 2004-08-04 University Of South Florida Rsv gene expression vaccine
WO2003053464A1 (en) * 2001-12-20 2003-07-03 Aventis Pasteur Limited Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus
EP1579001B1 (en) 2002-04-30 2013-02-13 University Of South Florida Materials and methods for use in the prevention and treatment of rna viral diseases
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
CA2518924C (en) * 2003-03-18 2016-06-07 Wyeth Holdings Corporation Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
EP2214711B1 (en) * 2007-10-25 2018-08-15 Trellis RSV Holdings, Inc. Anti-rsv g protein antibodies
WO2009147248A2 (en) 2008-06-05 2009-12-10 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
EP2370099B1 (en) * 2008-12-09 2016-04-20 Novavax, Inc. Modified rsv f proteins and methods of their use
CN105061592A (zh) 2009-06-05 2015-11-18 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
EP3178490B1 (en) * 2009-07-15 2022-04-20 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
NZ599148A (en) * 2009-10-06 2014-08-29 Medimmune Ltd Rsv-specific binding molecule
WO2011077035A1 (fr) * 2009-12-23 2011-06-30 Sanofi Pasteur Procede de culture de cellules adherentes
CN102199198A (zh) * 2011-03-28 2011-09-28 北京交通大学 人呼吸道合胞病毒f蛋白的纯化方法
CA2879915C (en) 2012-08-01 2022-07-05 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
HRP20240996T1 (hr) 2013-03-13 2024-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefuzija rsv f proteina i njihova uporaba
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
JP6479305B2 (ja) 2013-07-12 2019-03-06 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
EP3076999B1 (en) * 2013-12-02 2020-01-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant respiratory syncytial virus g protein fragments
JP6704074B2 (ja) * 2019-02-04 2020-06-03 株式会社Ｕｍｎファーマ ウイルス様粒子の精製方法
RU2746280C1 (ru) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Штамм респираторно-синцитиального вируса RSV/Novosibirsk/66Hl/2018 для использования в диагностике респираторно-синцитиальной вирусной инфекции и исследования эффективности противовирусных препаратов in vitro

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689622T2 (de) * 1986-01-14 1994-06-16 Univ North Carolina Impfstoffe gegen menschliche respiratorische viren.
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
EP0705109B2 (en) * 1993-05-25 2004-01-02 American Cyanamid Company Adjuvants for vaccines against respiratory syncytial virus
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation

Also Published As

Publication number Publication date
WO1998002457A1 (en) 1998-01-22
ES2141065T5 (es) 2009-02-16
CN1230197A (zh) 1999-09-29
US6020182A (en) 2000-02-01
ATE282633T1 (de) 2004-12-15
EP0942928A1 (en) 1999-09-22
HK1022704A1 (en) 2000-08-18
DE69731659T2 (de) 2006-03-02
CA2259594A1 (en) 1998-01-22
GR990300042T1 (en) 2000-01-31
ES2141065T3 (es) 2005-05-01
EP0942928B2 (en) 2008-08-13
US6309649B1 (en) 2001-10-30
DE69731659T3 (de) 2009-06-18
JP2000501418A (ja) 2000-02-08
AU716378B2 (en) 2000-02-24
CA2259594C (en) 2003-11-11
EP1477494A1 (en) 2004-11-17
AU3431197A (en) 1998-02-09
ES2141065T1 (es) 2000-03-16
EP0942928B1 (en) 2004-11-17
DE942928T1 (de) 2000-03-02
DE69731659D1 (de) 2004-12-23
CN1145639C (zh) 2004-04-14
RU2243234C2 (ru) 2004-12-27
NZ334115A (en) 2000-06-23

Similar Documents

Publication Publication Date Title
BR9712970A (pt) Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica
EP0912743B1 (fr) Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BR9915988A (pt) Vacina para peptidase c5a estreptocócica
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
WO2000077216A3 (en) Porcine circovirus vaccine in recombinant poxvirus
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
ES2150493T3 (es) Adyuvantes para vacunas contra el virus sincitico respiratorio.
CA2408328A1 (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
BR9712556A (pt) Plasmìdeo, composição farmacêutica, e, processo de imunizar um indivìduo contra um antìgeno
DE69940406D1 (de) Ine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält
CA2399172A1 (en) Cold-adapted equine influenza viruses
PT1015595E (pt) Peptidos derivados da proteina de ligacao (g) do virus sincicial respiratorio
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
ES2192559T3 (es) Vacuna para la proteccion de aves de corral contra la coccidiosis.
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
TW200505475A (en) Avian E. coli vaccine for protection against colibacillosis
DE69510858D1 (de) Mukosale Verabreichung von Pneumokokken-Antigenen
WO2002009749A3 (en) Respiratory syncytial virus vaccine
CO5300406A1 (es) Vacuna
WO2003022878A3 (en) Subunit respiratory syncytial virus vaccine preparation
EA200200743A1 (ru) Рекомбинантное ослабление вируса репродуктивного и респираторного синдрома свиней (prrsv)
AR009756A1 (es) Composicion farmaceutica para usar en el tratamiento de enfermedades inducidas por el virus sincitial respiratorio
BR9814958A (pt) Proteìna de cimento de tecido, composição farmacêutica, uso da proteìna de cimento de tecido, vacina, processos para produção de vacina, para ligação de tecido de animal e para preparação de uma protéina de cimento de tecido, molécula de ácido nucleico, vetor de expressão ou de clonagem, célula hospedeira, e, animal transgênico

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, SUGIRO O INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 10 (IX) E 13 DA LPI 9279/96.